Posts by Leo A. Kim, MD, PhD
-
RUNX1 Inhibition Proposed for Prevention, Treatment of Lung Injury in Severe COVID-19
Leo Am Kim, MD, PhD, and Joseph F. Arboleda-Velasquez, MD, PhD, of Mass Eye and Ear, and colleagues found that a small-molecule inhibitor of the RUNX1 transcription factor robustly ameliorates lung fibrosis in an animal model and reduces expression of host proteins critical to SARS-CoV-2 infection.
Biography
Dr. Leo Kim is a retina surgeon and a member of the Retina Service who has extensive experience in the management of retinal diseases associated with neovascularization or angiogenesis. These include diseases such as retinal vein occlusions, diabetic retinopathy and age-related macular degeneration.
A clinician scientist, Dr. Kim focuses his research on understanding the mechanisms of vitreoretinal disease. He is particularly interested in the mechanisms of retinal toxicity associated with the use of systemic medications such as tamoxifen. In addition, he performs research on the molecular mechanisms of proliferative diabetic retinopathy, evaluating the cell biology of fibrovascular membranes and the genetics of PDR. He also performs translational research on the prognosis of non-exudative age-related macular degeneration.
Mass Eye and Ear/Mass General Ophthalmology
An international center for ophthalmology treatment and research, Mass Eye and Ear/Massachusetts General Hospital is the primary teaching hospital of Harvard Medical School’s Department of Ophthalmology, and is consistently recognized as one of the nation’s top hospitals for eye care. Led by Chief and Chair Joan W. Miller, MD, the department provides seamless access to the most innovative care available anywhere in the world.
